Sun Pharmaceutical Industries Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints
- June 25, 2026
- Posted by: Kunal Singla
- Category: News
Sun Pharmaceutical Industries Q1 Results FY27: Uniresearch projects Revenue Rs 15,499 Cr | PAT Rs 2,651 Cr (34-analyst consensus). Q4 FY26: Rev Rs 14,612 Cr | PAT Rs 2,710 Cr.
The Sun Pharmaceutical Industries Q1 Results FY27 outlook is anchored on Q4 FY26 verified actuals and Uniresearch analysis applying the 34-analyst FY27 consensus to Q1 FY26 verified actuals. Uniresearch projects Revenue Rs 15,499 Cr (+11.9% YoY) and PAT Rs 2,651 Cr (+15.6% YoY). Prepared by Ankit Jaiswal.
Click Here – Get Free Investment Predictions
Sun Pharmaceutical Industries Q1 Results FY27 – Uniresearch Prediction
| Metric | Q1 FY26 Actual | Q1 FY27 Uniresearch Prediction | YoY Change | Source |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Revenue (Rs Cr) | 13,851 | 15,499 | +11.9% | Uniresearch | 34-analyst consensus applied to Q1 FY26 verified actual |
| PAT (Rs Cr) | 2,293 | 2,651 | +15.6% | Uniresearch | 34-analyst consensus applied to Q1 FY26 verified actual |
| Avg Analyst Target | Rs 2,040 | 12-month view | – | Analyst consensus (34 analysts) |
Predictions apply 34-analyst FY27 consensus (Rev +11.9%, PAT +15.6%) to Q1 FY26 verified actuals. Not guaranteed outcomes.
Sun Pharmaceutical Industries Q4 FY26 Key Metrics – Baseline for Sun Pharmaceutical Industries Q1 Results FY27
| Metric | Q4 FY26 Actual | YoY Change | Source |
|---|---|---|---|
| Revenue (Rs Cr) | 14,612 | +12.8% YoY | Consolidated quarterly financial data |
| PAT (Rs Cr) | 2,710 | +25.8% YoY | Consolidated quarterly financial data |
What Analysts Are Saying About Sun Pharmaceutical Industries Q1 Results FY27
Across 34 analysts covering Sun Pharmaceutical Industries, the FY27 consensus projects revenue growth of +11.9% and profit growth of +15.6%, with an average 12-month price target of Rs 2,040. The Sun Pharmaceutical Industries prediction reflects this consensus applied to verified Q1 FY26 actuals.
Key Watchpoints for Sun Pharmaceutical Industries
Revenue Delivery Against Consensus
Whether Sun Pharmaceutical Industries delivers Revenue Rs 15,499 Cr (+11.9% consensus growth) in Q1 Results FY27 is the primary watchpoint. Q1 FY26 base was Rs 13,851 Cr.
PAT Performance in Q1 FY27
Whether Sun Pharmaceutical Industries achieves PAT Rs 2,651 Cr (+15.6% growth from Q1 FY26 base of Rs 2,293 Cr) is the second major metric. Q4 FY26 PAT was Rs 2,710 Cr.
Risks to the Sun Pharmaceutical Industries Prediction
Below-Consensus Revenue Growth
If Revenue comes in below the +11.9% consensus estimate, actual revenue would fall short of the Rs 15,499 Cr target.
PAT Pressure
The PAT prediction of Rs 2,651 Cr could face pressure from cost factors not captured in the 34-analyst consensus of +15.6%.
Conclusion: Sun Pharmaceutical Industries
The Sun Pharmaceutical Industries Uniresearch prediction of Revenue Rs 15,499 Cr and PAT Rs 2,651 Cr is derived from the 34-analyst FY27 consensus applied to verified Q1 FY26 actuals. Track live updates and analyst calls on Univest.
Track Sun Pharmaceutical Industries Live on the Univest Screener
Download the Univest iOS App or Univest Android App for live Q1 Results FY27 alerts.
Disclaimer: Revenue and PAT actuals are sourced from consolidated quarterly financial data. Q1 Results FY27 Uniresearch predictions are derived by applying analyst consensus growth rates to verified Q1 FY26 actuals – these are analyst consensus projections and are not guaranteed outcomes. Investments in securities are subject to market risk. For educational purposes only. SEBI RA INH000013776.
Frequently Asked Questions on Sun Pharmaceutical Industries
What is Uniresearch’s PAT prediction for Sun Pharmaceutical Industries Q1 Results FY27?
Ans. Uniresearch projects Sun Pharmaceutical Industries PAT at Rs 2,651 Cr, applying 34-analyst FY27 profit growth consensus of +15.6% to Q1 FY26 verified PAT of Rs 2,293 Cr.
What is the Revenue prediction for Sun Pharmaceutical Industries Q1 Results FY27?
Ans. Sun Pharmaceutical Industries Revenue is projected at Rs 15,499 Cr, applying +11.9% FY27 revenue consensus to Q1 FY26 base of Rs 13,851 Cr.
What were Sun Pharmaceutical Industries Q1 Results FY27?
Ans. Q4 FY26 consolidated Revenue was Rs 14,612 Cr (+12.8% YoY) and PAT was Rs 2,710 Cr (+25.8% YoY).
How many analysts cover Sun Pharmaceutical Industries Q1 Results FY27?
Ans. The Sun Pharmaceutical Industries prediction is based on the consensus of 34 analysts with an average 12-month price target of Rs 2,040.
What is the FY27 growth consensus used in the Sun Pharmaceutical Industries Q1 Results FY27 prediction?
Ans. The FY27 consensus used is revenue growth of +11.9% and profit growth of +15.6%, based on 34 analyst calls.
What are the risks to the Sun Pharmaceutical Industries Q1 Results FY27?
Ans. Key risks include below-consensus revenue growth (target: +11.9%) and unexpected cost pressures impacting the +15.6% PAT consensus.
What is the Q1 FY26 base for the Sun Pharmaceutical Industries Q1 Results FY27?
Ans. Q1 FY26 consolidated Revenue was Rs 13,851 Cr and PAT was Rs 2,293 Cr, the base for the Sun Pharmaceutical Industries Uniresearch prediction.
